Entries by

Tetrahydrocannabinol and cannabidiol oromucosal spray in resistant multiple sclerosis spasticity: consistency of response across subgroups from the SAVANT randomized clinical trial.

Authors: Sven G. Meuth, Thomas Henze, Ute Essner, Christiane Trompke, Carlos Vila Silván Published in International Journal of Neuroscience Abstract Objective: To determine whether differences in disability status, spasticity severity, and spasticity duration at treatment start in patients with resistant multiple sclerosis (MS) spasticity might influence response to add-on tetrahydrocannabinol:cannabidiol (THC:CBD) oromucosal spray (nabiximols) versus…

February 17, 2020 by

Factors Moderating the Association Between Cannabis Use and Psychosis Risk: A Systematic Review.

Authors: Sanne J. van der Steur, Albert Batalla, Matthijs G. Bossong Published in Brain Sciences 12 February 2020   Abstract Increasing evidence indicates a relationship between cannabis use and psychosis risk. Specific factors, such as determinants of cannabis use or the genetic profile of cannabis users, appear to moderate this association. The present systematic review…

February 12, 2020 by

Lifetime Average Cannabis Use in Relation to Hypertriglyceridemic Waist Phenotype in U.S. Adults: A Population-Based Cross-Sectional Study

Authors: Gerard Ngueta Published in Cannabis and Cannabinoid Research 11 February 2020   Abstract Background and Aims: With a growing number of states legalizing recreational or medical cannabis, prevalence of cannabis users is expected to markedly increase in the future. We aim to determine the association between lifetime cannabis use and the likelihood for hypertriglyceridemic…

February 11, 2020 by

Response to UK Medical Cannabis Guidelines

Physicians from the UK give their critiques of recent medical cannabis regulations, noting the narrow window of qualifying conditions that do not include chronic pain, as well as advocating for the use of lower-cost, whole-plant flowers for patients.

February 4, 2020 by

The use of cannabis for Hyperemesis Gravidarum (HG).

Authors: Gideon Koren, Rana Cohen
Journal of Cannabis Research, 30 January 2020
—
Background: Hyperemesis Gravidarum (HG) responds only partially to standard antiemetic medications. Cannabis has been known to possess antiemetic effects and there are several medicinal cannabinoids used as anti -emetics for cancer chemotherapy. Its favorable use for HG has be…

January 30, 2020 by